Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$9.19 USD
+0.20 (2.22%)
Updated Nov 5, 2025 04:00 PM ET
After-Market: $9.18 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Amicus Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
FOLD 9.19 +0.20(2.22%)
Will FOLD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for FOLD
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
Other News for FOLD
FOLD: Goldman Sachs Raises Price Target but Maintains Neutral Rating | FOLD Stock News
Cantor Fitzgerald Sticks to Its Buy Rating for Amicus (FOLD)
Morgan Stanley Sticks to Their Buy Rating for Amicus (FOLD)
Is FOLD ready to move higher? Pocket Pivot shows up after rising 1.47%
Amicus price target raised to $11 from $9 at Goldman Sachs